<DOC>
	<DOCNO>NCT01781806</DOCNO>
	<brief_summary>The purpose study evaluate safety , acceptability feasibility delivery PrEP PEP part combination HIV prevention service high-risk MSM transgender woman .</brief_summary>
	<brief_title>A Demonstration Project Add Pre- Post-exposure Prophylaxis Combination HIV Prevention Services</brief_title>
	<detailed_description>Two community-based site ( Los Angeles Gay Lesbian Center [ LAGLC ] The OASIS Clinic ) serve facility participant may present screen prevention service . At site , eligibility criterion assess , HIV , STD laboratory test perform , HIV prevention service referral initiate . Follow-up monthly basis first three month , de-escalated every-3-month interval . The program stratifies participants two cohort basis sexual risk behavior : low-moderate risk cohort ( LM ) high-risk cohort ( H ) . Participants LM cohort provide customized prevention package ( CPP ) include access post-exposure prophylaxis ( PEP ) emergency HIV prevention event unanticipated HIV exposure . Participants H cohort provide CPP include daily Truvada-based PrEP . All participant follow 48 week . Participants LM cohort , longitudinal sexual risk behavior surveillance , report increase level sexual risk-taking meet enrollment criterion H-cohort transition H-cohort . At follow-up visit , careful safety assessment make , include signs/symptoms laboratory assessment . STI test perform 3 month interval . An escalating-intensity adherence intervention implement base real-time serum tenofovir level . A computer-assisted self-interview ( CASI ) use capture detail sexual risk , adherence , substance use behavior .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>At least 18 year age Able understand provide consent English Spanish Self identify MSM , MSM/W , Transgender ( MTF ) At least one male sex partner anal intercourse prior 12 month HIV negative EIA VL Creatinine clearance â‰¥ 60 ml/min ( via CockcroftGault formula ) No sign symptom suggestive primary HIV infection ( PHI ) . Participants &lt; 18 year age Unable understand provide consent English Spanish Known find test HIV positive Any condition , opinion intake provider , seriously compromise participant 's ability comply protocol , include adherence PEP PrEP medication dose Use Antiretroviral therapy ( ART ) take indication ( i.e . PEP PrEP ) within 60 day study entry Previous participation HIV vaccine trial . Participants document received placebo exclude . Signs symptoms suspicious PHI .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>